Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide Long-Term Extension in Children With Achondroplasia
NCT03989947Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2019
- Primary completion
- May 2038
- Countries
- 4
01
Overview
A Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Jun 2019; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT03989947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989947.